Literature DB >> 21851453

Cost of depression among adults in Japan in 2005.

Mitsuhiro Sado1, Keita Yamauchi, Norito Kawakami, Yutaka Ono, Toshiaki A Furukawa, Masao Tsuchiya, Miyuki Tajima, Haruo Kashima, Yoshibumi Nakane, Yoshikazu Nakamura, Akira Fukao, Itsuko Horiguchi, Hisateru Tachimori, Noboru Iwata, Hidenori Uda, Hideyuki Nakane, Makoto Watanabe, Masashi Oorui, Kazushi Funayama, Yoichi Naganuma, Yukihiro Hata, Masayo Kobayashi, Tadayuki Ahiko, Yuko Yamamoto, Tadashi Takeshima, Takehiko Kikkawa.   

Abstract

AIM: Major depression is expected to become the leading contributor to disease burden worldwide by 2020. Previous studies have shown that the societal cost of depression is not less than that of other major illnesses, such as cardiovascular diseases or AIDS. Nevertheless, the cost of depression in Japan has never been examined. The goal of the present study was to estimate the total cost of depression in Japan and to clarify the characteristics of this burden.
METHODS: A prevalence-based approach was adopted to measure the total cost of depression. The total cost of depression was regarded as being comprised of the direct cost, morbidity cost and mortality cost. Diagnoses included in this study were depressive episodes and recurrent depressive disorder according to the ICD-10 or major depressive disorder according to the DSM-IV. Data were collected from publicly available statistics and the World Mental Health Japan Survey database.
RESULTS: The total cost of depression among adults in Japan in 2005 was estimated to be ¥2.0 trillion. The direct cost was ¥0.18 trillion. The morbidity cost was ¥0.92 trillion, while the mortality cost was ¥0.88 trillion.
CONCLUSION: The societal costs caused by depression in Japan are enormous, as in other developed countries. Low morbidity costs and extremely high mortality costs are characteristic in Japan. Effective interventions for preventing suicide could reduce the societal costs of depression.
© 2011 The Authors. Psychiatry and Clinical Neurosciences © 2011 Japanese Society of Psychiatry and Neurology.

Entities:  

Mesh:

Year:  2011        PMID: 21851453     DOI: 10.1111/j.1440-1819.2011.02237.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  16 in total

1.  Cost-effectiveness analyses of augmented cognitive behavioral therapy for pharmacotherapy-resistant depression at secondary mental health care settings.

Authors:  Mitsuhiro Sado; Akihiro Koreki; Akira Ninomiya; Chika Kurata; Dai Mitsuda; Yasunori Sato; Toshiaki Kikuchi; Daisuke Fujisawa; Yutaka Ono; Masaru Mimura; Atsuo Nakagawa
Journal:  Psychiatry Clin Neurosci       Date:  2021-09-17       Impact factor: 12.145

2.  Adding smartphone-based cognitive-behavior therapy to pharmacotherapy for major depression (FLATT project): study protocol for a randomized controlled trial.

Authors:  Norio Watanabe; Masaru Horikoshi; Mitsuhiko Yamada; Shinji Shimodera; Tatsuo Akechi; Kazuhira Miki; Masatoshi Inagaki; Naohiro Yonemoto; Hissei Imai; Aran Tajika; Yusuke Ogawa; Nozomi Takeshima; Yu Hayasaka; Toshi A Furukawa
Journal:  Trials       Date:  2015-07-07       Impact factor: 2.279

3.  Cost of anxiety disorders in Japan in 2008: a prevalence-based approach.

Authors:  Mitsuhiro Sado; Sayuri Takechi; Ataru Inagaki; Daisuke Fujisawa; Akihiro Koreki; Masaru Mimura; Kimio Yoshimura
Journal:  BMC Psychiatry       Date:  2013-12-18       Impact factor: 3.630

4.  Concise set of files for smooth return to work in employees with mental disorders.

Authors:  Kiyoshi Yoshitsugu; Yuko Kuroda; Yuji Hiroyama; Nobuhisa Nagano
Journal:  Springerplus       Date:  2013-11-23

5.  Evaluation of factors associated with psychiatric patient dropout at a university outpatient clinic in Japan.

Authors:  Atsumi Minamisawa; Jin Narumoto; Isao Yokota; Kenji Fukui
Journal:  Patient Prefer Adherence       Date:  2016-09-20       Impact factor: 2.711

6.  Japan Unified Protocol Clinical Trial for Depressive and Anxiety Disorders (JUNP study): study protocol for a randomized controlled trial.

Authors:  Masaya Ito; Yasuyuki Okumura; Masaru Horikoshi; Noriko Kato; Yuki Oe; Mitsuhiro Miyamae; Naotsugu Hirabayashi; Ayako Kanie; Atsuo Nakagawa; Yutaka Ono
Journal:  BMC Psychiatry       Date:  2016-03-18       Impact factor: 3.630

7.  Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.

Authors:  Diego Novick; William Montgomery; Josep Maria Haro; Maria Victoria Moneta; Gang Zhu; Li Yue; Jihyung Hong; Héctor Dueñas; Roberto Brugnoli
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-23       Impact factor: 2.570

8.  Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East.

Authors:  Jihyung Hong; Diego Novick; Maria Victoria Moneta; Ahmed El-Shafei; Héctor Dueñas; Josep Maria Haro
Journal:  Clin Pract Epidemiol Ment Health       Date:  2017-09-30

9.  The cost of schizophrenia in Japan.

Authors:  Mitsuhiro Sado; Ataru Inagaki; Akihiro Koreki; Martin Knapp; Lee Andrew Kissane; Masaru Mimura; Kimio Yoshimura
Journal:  Neuropsychiatr Dis Treat       Date:  2013-05-30       Impact factor: 2.570

10.  Cost-effectiveness of family psychoeducation to prevent relapse in major depression: results from a randomized controlled trial.

Authors:  Shinji Shimodera; Toshi A Furukawa; Yoshio Mino; Kae Shimazu; Atsushi Nishida; Shimpei Inoue
Journal:  BMC Psychiatry       Date:  2012-05-14       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.